PD-1 Monoclonal Antibody Patent Application for Cancer Treatment

Fri, 10 Apr 2026 02:46:17 +0000
Intellectual Property

The USPTO published patent application US20260098092A1 for monoclonal antibodies targeting human programmed cell death protein 1 (PD-1) and methods for treating cancer using said antibodies and antigen-binding fragments. The application was filed October 4, 2023, naming seven inventors including Trairak Pisitkun and colleagues. Pharmaceutical and biotech companies developing PD-1/PD-L1 pathway cancer immunotherapies should monitor for this application's progression to grant.